Enterprise Value
1.434B
Cash
110.8M
Avg Qtr Burn
-24.5M
Short % of Float
9.30%
Insider Ownership
46.08%
Institutional Own.
24.25%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rayaldee (calcifediol ER capsules) Details CKD (Chronic kidney disease) | Approved Quarterly sales | |
NGENLA® Somatrogon Details Pediatric growth hormone deficiency | NDA FDA meeting | |
OPK88003 (oxyntomodulin analog) (FLP-1 agonist) Details Type 2 diabetes | Phase 2 Update | |
Rayaldee Details COVID-19 | Phase 2 Update |